Copyright
©The Author(s) 2026.
World J Cardiol. Jan 26, 2026; 18(1): 112321
Published online Jan 26, 2026. doi: 10.4330/wjc.v18.i1.112321
Published online Jan 26, 2026. doi: 10.4330/wjc.v18.i1.112321
Table 1 Baseline characteristics, n (%)
| Total (n = 128) | Fixed dose (n = 78) | Weight-based (n = 50) | |
| Age (mean ± SD), years | 67 ± 11 | 68 ± 11 | 66 ± 11 |
| Gender | |||
| Male | 87 (68) | 45 (58) | 42 (84) |
| Female | 41 (32) | 33 (42) | 8 (16) |
| BMI (mean ± SD, kg/m2) | 28.97 ± 5.1 | 28.23 ± 5 | 30 ± 5 |
| Underweight | 1 (0.8) | 1 (1.3) | 0 (0) |
| Normal | 28 (21.9) | 19 (24.4) | 9 (18) |
| Overweight | 48 (37.5) | 31 (39.7) | 17 (34) |
| Obese | 51 (39.8) | 27 (34.6) | 24 (48) |
| Weight (mean ± SD, kg) | 85.1 ± 17.8 | 79.9 ± 15.8 | 93.4 ± 17.7 |
| Medical history | |||
| Chronic kidney disease (eGFR < 60) | 3 (2) | 2 (3) | 1 (2) |
| Chronic liver disease | 4 (3) | 3 (4) | 1 (2) |
| Bleeding diathesis | 0 (0) | 0 (0) | 0 (0) |
| Thrombocytopenia (< 100000) | 0 (0) | 0 (0) | 0 (0) |
| Anticoagulation (DOAC or warfarin) | 15 (12) | 10 (13) | 5 (10) |
| On anti-platelets | 97 (76) | 58 (74) | 39 (78) |
| Indication | |||
| FFR | 114 (89) | 64 (82) | 50 (100) |
| Microvascular | 14 (11) | 14 (18) | 0 (0) |
| Access site | |||
| Radial | 117 (91) | 71 (91) | 46 (92) |
| Femoral | 11 (9) | 7 (9) | 4 (8) |
| Median heparin dose IU, median (IQR) | 5000 (5000, 5000) | 8000 (7000, 9000) | |
| BARC bleeding score | |||
| 0 (no bleeding) | 110 (85) | 65 (83.3) | 44 (88) |
| 1 | 18 (14) | 12 (15.4) | 6 (12) |
| 2 | 1 (1) | 1 (1.3) | 0 (0) |
| 3 | 0 (0) | 0 (0) | 0 (0) |
| 4 | 0 (0) | 0 (0) | 0 (0) |
| 5 | 0 (0) | 0 (0) | 0 (0) |
| Radial artery occlusion | 0 (0) | 0 (0) | 0 (0) |
| Stroke | 0 (0) | 0 (0) | 0 (0) |
| Post-procedure MI | 0 (0) | 0 (0) | 0 (0) |
| Length of stay days, median (IQR) | 1 (1, 4) | 1 (1, 3) | 1 (1, 4) |
Table 2 Logistic regression analysis for bleeding predictors
| Predictor | Unadjusted OR (95%CI) | P value | Adjusted OR (95%CI) | P value |
| Sex | 0.60 (0.20-1.89) | 0.424 | ||
| Access site | 2.35 (0.36-11.19) | 0.210 | 2.09 (0.42-8.22) | 0.318 |
| Antiplatelet use | 3.06 (0.66-28.95) | 0.158 | 2.90 (0.76-19.1) | 0.713 |
| Anticoagulant use | 0.87 (0.09-4.41) | 1 |
- Citation: Ralota KK, Tuncer D, Htun NM, Samuel R, Gupta V, Lew R, Layland J. Fixed vs weight-based heparin dosing in stable patients undergoing diagnostic coronary physiology studies. World J Cardiol 2026; 18(1): 112321
- URL: https://www.wjgnet.com/1949-8462/full/v18/i1/112321.htm
- DOI: https://dx.doi.org/10.4330/wjc.v18.i1.112321
